Home » Authors » Jim Shrine

Articles by Jim Shrine

NeurogesX Presents Positive Data From Trial Of Pain Patch

Nov. 1, 2011

No Abstract

NewCo News: Aileron Raises $7M For Work On Peptide Technology Platform

Nov. 1, 2011

No Abstract

KineMed Applying Translation Technologies In Deal With Bayer

Nov. 1, 2011

No Abstract

Renovis Cuts Staff As Focus Moves To Preclinical Programs

Nov. 1, 2011

No Abstract

Santhera Starts Phase III Trial In Friedreich's Ataxia Patients

Oct. 1, 2007

Santhera Starts Phase III Trial In Friedreich's Ataxia Patients

Oct. 1, 2007

NPS, Nycomed Enter Potential $185M Deal Covering Gattex

Sep. 27, 2007

NPS, Nycomed Enter Potential $185M Deal Covering Gattex

Sep. 27, 2007

Sonus Crashes On Failed Pivotal Trial Of Tocosol Paclitaxel Drug

Sep. 25, 2007

Sonus Crashes On Failed Pivotal Trial Of Tocosol Paclitaxel Drug

Sep. 25, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Nov. 12, 2025.
Could restricting diversity efforts stall women’s health research?
BioWorld
Recent progress in redressing the historical underfunding and neglect of women’s health could be undermined by the backlash against diversity, equity and...
Alkermes’ alixorexton hits endpoints in narcolepsy phase II
BioWorld
Alkermes plc’s placebo-controlled phase II study of alixorexton in treating narcolepsy type 2 (NT2) hit its dual primary endpoints, producing statistically...
Pazdur ‘optimal fit’ to lead FDA’s CDER
BioWorld
In reaching within to name 26-year FDA veteran Richard Pazdur as the next CDER director, FDA Commissioner Marty Makary likely chose the best possible person to...